<div id="readability-page-1"><p>Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) is expected to be releasing its  Q4 2025 results before the market opens on Monday, December 22nd. Analysts expect the company to announce earnings of ($0.13) per share for the quarter. Individuals can check  the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, November 25, 2025 at 8:30 AM ET.</p><ul><li>Short-Squeeze Target Anavex Life Sciences Gains Traction</li></ul><p>Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last issued its earnings results on Tuesday, November 25th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. During the same period in the previous year, the business earned ($0.14) earnings per share.  On average, analysts expect Anavex Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year. </p><div><p><span></span><span>Get <strong>Anavex Life Sciences</strong> alerts:</span></p></div><h2>Anavex Life Sciences Trading Down 2.2%</h2><p>AVXL stock opened at $4.02 on Monday. The company has a market cap of $359.19 million, a PE ratio of -7.44 and a beta of 1.16. The stock has a 50-day moving average price of $6.45 and a two-hundred day moving average price of $8.56. Anavex Life Sciences has a 12-month low of $2.86 and a 12-month high of $14.44. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of analysts have recently issued reports on AVXL shares. HC Wainwright  reiterated a &#34;buy&#34; rating on shares of Anavex Life Sciences in a report on Friday, November 28th. Jones Trading downgraded shares of Anavex Life Sciences from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, October 24th. Wall Street Zen lowered shares of Anavex Life Sciences from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, August 23rd. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Anavex Life Sciences in a report on Monday, December 1st. Finally, D. Boral Capital  reaffirmed a &#34;buy&#34; rating on shares of Anavex Life Sciences in a research report on Wednesday, November 26th. Two analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has issued  a Sell rating to the company. According to data from MarketBeat.com, Anavex Life Sciences presently has an average rating of &#34;Hold&#34; and an average price target of $44.00.</p><p><b>View Our Latest Stock Analysis on Anavex Life Sciences</b></p><h2>Hedge Funds Weigh In On Anavex Life Sciences</h2><p>Institutional investors have recently made changes to their positions in the business. State of Wyoming acquired a new stake in  Anavex Life Sciences in the second quarter valued at $26,000.  Quarry LP bought a new stake in shares of  Anavex Life Sciences in the 3rd quarter worth about $36,000.  Russell Investments Group Ltd. raised its stake in shares of  Anavex Life Sciences by 11,540.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,984 shares of the biotechnology company's stock valued at $62,000 after purchasing an additional 6,924 shares in the last quarter.  Prudential Financial Inc. bought a new position in shares of  Anavex Life Sciences during the second quarter worth about $95,000.  Finally, Sei Investments Co. bought a new position in shares of  Anavex Life Sciences during the second quarter worth about $107,000. 31.55% of the stock is owned by institutional investors and hedge funds. </p><h2>Anavex Life Sciences Company Profile</h2> (Get Free Report)<p>Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.</p><h2>See Also</h2><ul><li>Five stocks we like better than Anavex Life Sciences</li><li>Profitably Trade Stocks at 52-Week Highs</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>What is the Shanghai Stock Exchange Composite Index?</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>Most active stocks: Dollar volume vs share volume</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZYTA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZYTA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Anavex Life Sciences Right Now?</h2><p>Before you consider Anavex Life Sciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.</p><p>While Anavex Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AVXL

<p>Anavex Life Sciences (NASDAQ:AVXL) will release its Q4 2025 earnings on December 22, with analysts expecting a loss of $0.13 per share. The company previously reported a loss of $0.11 per share, beating estimates. AVXL stock is trading at $4.02, down 2.2%. Analysts have mixed ratings, with an average "Hold" rating and a price target of $44.00. Institutional investors have adjusted their positions, with 31.55% ownership. Anavex develops treatments for CNS diseases, including Alzheimer's and Parkinson's.</p>

Anavex Life Sciences (AVXL) Projected to Post Quarterly Earnings on Monday